Dose-finding clinical assay of triletide in gastric and duodenal ulceration

Three groups of 15 patients with endoscopically confirmed active gastric or duodenal ulcer were treated over a period of 8 weeks with daily doses of 1, 1.5 or 2 g triletide, an anti-ulcer agent which acts by enhancing the mucosal defence capacity. Intensity of epigastric pain and of heartburn and we...

Ausführliche Beschreibung

Bibliographische Detailangaben
Veröffentlicht in:Interim guidelines for the control of infections with Vero cytotoxin producing Escherichia coli (VTEC). Subcommittee of the PHLS Working Group on Vero cytotoxin producing Escherichia coli (VTEC). - 1995. - 4(1985), 3 Spec No vom: 15., Seite 146-54
1. Verfasser: Waucquez, J L (VerfasserIn)
Format: Aufsatz
Sprache:English
Veröffentlicht: 1985
Zugriff auf das übergeordnete Werk:Interim guidelines for the control of infections with Vero cytotoxin producing Escherichia coli (VTEC). Subcommittee of the PHLS Working Group on Vero cytotoxin producing Escherichia coli (VTEC)
Schlagworte:Clinical Trial Journal Article Randomized Controlled Trial Antacids Anti-Ulcer Agents Oligopeptides triletide 50Q6LI773L